000			02195cam a2200325 4500500
005			20250121154404.0
041			_afre
042			_adc
100	1	0	_aMarsch, Wolfgang C. _eauthor
700	1	0	_a Komatsuzaki, Shoko _eauthor
700	1	0	_a Mueller, Astrid _eauthor
700	1	0	_a Hagemann, Monika _eauthor
700	1	0	_a Lange, Danica _eauthor
700	1	0	_a Maemecke, Larissa _eauthor
700	1	0	_a Villavicencio-Lorini, Pablo _eauthor
700	1	0	_a Hoffmann, Katrin _eauthor
245	0	0	_aLivedoid vasculopathy: does hyperhomocysteinaemia play an aetiological role?
260			_c2019.
500			_a14
520			_aBackground: Livedoid vasculopathy (LV) has been shown to be associated with hypercoagulability. However, relevant genetic and exogenous thrombophilic factors are not fully determined. Objectives: To evaluate the frequency of hyperhomocysteinaemia (HHCE) and genotypes of hypercoagulative factors in LV patients. Material and Methods: Plasma homocysteine level was measured in 42 LV patients. Polymorphism of MTHFR (677C > T and 1298A > C), PAI1 (-675 5G/4G and -844A > G), and F2 (20210G > A), and the F5 Leiden mutation, as well as biochemical parameters for hypercoagulability, were analysed. Results: Of the LV patients, 62% revealed mild HHCE. Polymorphisms of MTHFR were observed in 75% and 56% and the PAI1 -675 5G/4G polymorphism in 100% and 83% of patients with and without HHCE, respectively. All LV patients with renal failure had mild HHCE. A high level of comorbidity of hypertension (99%) and diabetes type 2 (44%) were noted. Conclusion: HHCE seems to play a major pathogenetic role in LV. A high prevalence of further procoagulative factors might support the view that LV is a “complex disease”.
690			_aMTHFR
690			_aPAI1
690			_aF2
690			_alivedoid vasculopathy
690			_ahypercoagulative factor
690			_ahyperhomocysteinaemia
690			_aF5 Leiden
786	0		_nEuropean Journal of Dermatology | 29 | 3 | 2019-05-01 | p. 287-293 | 1167-1122
856	4	1	_uhttps://shs.cairn.info/revue-european-journal-of-dermatology-2019-3-page-287?lang=en&redirect-ssocas=7080
999			_c602118 _d602118